Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations

48Citations
Citations of this article
87Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe leading to significantly higher risk for premature heart disease in those affected. As treatment beginning early in life is highly effective in preventing heart disease and cost-effective in these patients, screening for FH is crucial. It has therefore now been recognized by the European Commission Public Health Best Practice Portal as an effective strategy. Model programmes exist in Europe to identify young individuals with FH, which are based on cascade screening of first-degree relatives of affected individuals, universal screening for high cholesterol, opportunistic screening of high-risk individuals, or a combination of the above approaches. Recommendations presented herein to improve identification of FH emphasize that every country should have an FH screening programme. These programmes should be adapted from existing strategies to best fit the individual country’s healthcare system, governments should provide financial support for these programmes and related care, and further research to optimize care and implementations should be conducted.

Cite

CITATION STYLE

APA

Gidding, S. S., Wiegman, A., Groselj, U., Freiberger, T., Peretti, N., Dharmayat, K. I., … Geanta, M. (2022, December 1). Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. European Journal of Preventive Cardiology. Oxford University Press. https://doi.org/10.1093/eurjpc/zwac200

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free